🇺🇸 FDA
Pipeline program

R932333

C-932333-002

Phase 2 small_molecule completed

Quick answer

R932333 for Lupus Erythematosus, Discoid is a Phase 2 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
RIGEL PHARMACEUTICALS INC
Indication
Lupus Erythematosus, Discoid
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials